12Nov
Conferences
European Charcot Foundation annual meeting
Until 14 Nov
This meeting in Baveno and online will discuss treatment benefits and risks over the course of MS.
News
What is happening in MS research: trial results, regulatory decisions and new papers, each linked to the trials and medicines it is about.
How sure is the date?ConfirmedCompany guidanceRegistry estimate
November 2026
19Nov
Conferences
PACTRIMS 2026, the Asia-Pacific MS meeting
Until 21 Nov
The meeting takes place in Taipei. One organiser note gives the closing date as 22 November rather than 21 November.
21Nov
Trial results
RAM-MS: stem cell transplant compared with strong MS medicines
The trial compares stem cell transplant with alemtuzumab, cladribine or ocrelizumab. Main data collection is due to end, with two year results previously expected in the second half of 2026.
Sometime in Early Nov 2026
Est.2026
Other
Registration opens for the AAN 2027 neurology meeting
Early Nov 2026
Registration is expected to open for the neurology meeting on 1 to 5 May 2027.
December 2026
4Dec
Conferences
MENACTRIMS, the Middle East and North Africa MS meeting
Until 5 Dec
This regional MS research meeting takes place in Dubai.
Sometime in Q4 2026
Q42026
Trial results
INFORM-MS: foralumab nasal spray in non-active SPMS
Q4 2026
The company expects first results in the last quarter of 2026, having previously said October. No results were reported as of the 26 October source check.
Sometime in 2026
Year2026
Trial results
ENSURE-1 and 2: vidofludimus compared with placebo in relapsing MS
By end-2026
Two large trials measure time to the first relapse. If the results are positive, the company plans a US application in the middle of 2027.
Sometime in End-2026
Est.2026
Filings
Application to start trials of privosegtor for MS relapses
End-2026
Oculis plans to apply to the FDA towards the end of 2026 after receiving early advice on testing privosegtor.
Sometime in H2 2026
H22026
Other
Large trial of vidofludimus in progressive MS due to start
H2 2026
Immunic plans to start a large progressive MS trial later in 2026, following the earlier CALLIPER trial.
January 2027
Sometime in before 10 Jan 2027
Est.2027
Regulatory decisions
FDA decision on Enspryng (satralizumab) for MOGAD
By 10 Jan 2027
Roche reports a review target for satralizumab in MOGAD. The company announcement is not a regulator confirmation or a promise of approval.
March 2027
11Mar
Conferences
ACTRIMS Forum 2027
Until 13 Mar
This MS research meeting takes place in Phoenix, Arizona.
11Mar
Conferences
EBMT 2027, the European transplant meeting
Until 14 Mar
The transplant meeting in Rotterdam may include results relevant to stem cell transplantation in MS.
Sometime in Early 2027
Est.2027
Other
Kyverna update on miv-cel plans in progressive MS
Early 2027
Kyverna expects to provide an update on its plans for miv cel after an FDA designation for non active SPMS.
Sometime in Q1 2027
Q12027
Trial results
Foralumab nasal spray results in Alzheimer's disease
Q1 2027
The trial tests the same nasal spray as INFORM MS in a different disease. Its results may inform research on calming brain immune cells.
April 2027
Sometime in Late Mar / early Apr 2027
May 2027
1May
Conferences
AAN Annual Meeting 2027
Until 5 May
The American Academy of Neurology meeting takes place in Washington, DC, and online.
6May
Trial results
FREXALT-1 and 2: frexalimab compared with teriflunomide in relapsing MS
The registry estimates when the trials will finish data collection. They compare frexalimab with teriflunomide using the yearly relapse rate.
30May
Other
World MS Day
World MS Day brings people together to raise awareness of multiple sclerosis.
June 2027
2Jun
Conferences
CMSC Annual Meeting 2027
Until 4 Jun
The Consortium of MS Centers meeting takes place in San Diego. Listings disagree about the closing date, so the dates await confirmation on the CMSC site.
12Jun
Conferences
EAN Congress 2027
Until 15 Jun
The European Academy of Neurology congress takes place in Gothenburg, Sweden.
Sometime in Mid-2027
Est.2027
Filings
US application for vidofludimus (if the ENSURE trials succeed)
Mid-2027
Immunic plans a US application if the ENSURE trials succeed. Its target for approval in 2028 remains a company forecast.
July 2027
15Jul
Trial results
FREXCITE: under-the-skin compared with drip frexalimab
The trial measures how frexalimab is absorbed when given as an injection under the skin rather than an infusion.
30Jul
Trial results
DELIVER-MS: strong treatment from the start compared with step-up
The trial asks whether starting with stronger medicines gives better outcomes than moving to them later. It plans to include 800 people.
Sometime in July 2027
Est.2027
Trial results
StarMS: stem cell transplant compared with strong MS medicines (UK)
July 2027
This phase 3 UK trial compares stem cell transplant with strong MS medicines in 94 participants. The source expects results in July 2027.
October 2027
5Oct
Conferences
ECTRIMS Global 2027
Until 8 Oct
The MS congress takes place in Vienna, with a preliminary day on 5 October and the main meeting on 6 to 8 October. The patient community day is on 8 October, and registration opens in February 2027.
December 2027
31Dec
Trial results
ChariotMS: cladribine in advanced MS
The trial studies arm and hand function in 200 people who use walking aids or a wheelchair. First results are expected in 2027 to 2028.
Sometime in Dec 2027
Est.2027
Trial results
PIONEER-1: privosegtor for optic neuritis
Dec 2027
This phase 3 optic neuritis trial includes people with and without MS. First results may be announced before its estimated completion date.
June 2028
17Jun
Conferences
EAN Congress 2028, the European neurology meeting
Until 20 Jun
The European neurology congress takes place in Rotterdam.
December 2028
Sometime in 2028
Year2028
Trial results
TARGET-EBV: antiviral tenofovir added to anti-CD20 treatment
2028
The phase 2b trial tests tenofovir alongside anti CD20 treatment. Its main measure is a marker of nerve damage in spinal fluid.
January 2029
8Jan
Trial results
Horizon: mRNA vaccine against Epstein–Barr virus in relapsing MS
The phase 2 trial compares an Epstein Barr virus vaccine with placebo in 180 people diagnosed with MS within the previous two years.
June 2029
23Jun
Conferences
EAN Congress 2029, the European neurology meeting
Until 26 Jun
The European neurology congress takes place in Vienna.
August 2030
6Aug
Trial results
BEAT-MS: stem cell transplant compared with best available medicines
The registry moved the estimated end of main data collection from October 2026 to August 2030 on 15 October 2026.
October 2030
1Oct
Trial results
Rapcabtagene autoleucel, a CAR-T cell therapy, in relapsing MS
This early trial tests CAR T cell therapy in about 28 people whose MS remains active despite treatment. A separate trial covers progressive MS.
Recently passed (1)
31Oct
Trial results
Under-the-skin ublituximab trial (every 2 or 3 months, compared with drip)
Main data collection is due to end. TG Therapeutics expects first results by the end of 2026 or early 2027.
Checking the recorded outcome…
Expected, no date yet
- Fenebrutinib EU and other ex-US filings
No EU submission announced. NICE appraisals for RMS and PPMS scheduled to match regulatory timing (dates TBC).
Roche · Source ↗
- Remibrutinib global RMS filings
Company plans global submissions. No dates given. Already approved in the US for chronic hives.
Novartis · Source ↗
- REMASTER (remibrutinib in SPMS) readout
Ongoing, with registry primary completion in December 2030.
Novartis · Source ↗
- Tolebrutinib US path after CRL
No resubmission or new PDUFA date announced. NICE appraisal paused at company request.
Sanofi · Source ↗
- TREAT-MS results
Trial completed 31 Aug 2026 (900 participants). Results not yet released.
PCORI-funded consortium (Johns Hopkins et al.) · Source ↗
- GA Depot (monthly glatiramer) EU decision
Under review in Germany for relapsing MS. Launch targeted 2027 if approved. FDA declined in 2024.
Mapi Pharma · Source ↗
- Lucid-MS Phase 2 start (progressive MS)
FDA cleared Aug 2026. Sites are preparing to open.
Quantum BioPharma · Source ↗
- C-CAR168 Phase 1b/2 start (progressive MS)
FDA cleared Sep 2026. Around 6 to 24 people are planned in phase 1b and around 95 in phase 2.
AbelZeta · Source ↗
- CTA313 US basket Phase 1b start
FDA cleared Jun 2026 (progressive MS, lupus, autoimmune encephalitis).
Imviva Biotech · Source ↗
- PTD802 first-in-human Phase 1
Oral GPR17 blocker for remyelination. FDA and UK cleared.
Pheno Therapeutics / UCB · Source ↗
- Orelabrutinib PriMroSe / Monarch readouts
Phase 3 ongoing. Registry primary completions June 2030.
Zenas BioPharma · Source ↗
- Ocrelizumab biosimilar (IV + SC)
Licensing deal Jul 2026. Entry depends on patents and exclusivity.
Teva / Polpharma Biologics · Source ↗
- TAG-MS: pegsebrenatide (GLP-1) in progressive MS
Phase 2, about 120 people, 96 weeks of treatment. The first participant received treatment in May 2026.
Neuraly / Johns Hopkins · Source ↗
FDA and EMA dates
Regulator sources checked 2026-10-25. Company forecasts are not regulator-confirmed decisions. Registry completion dates are estimates for data collection, not scheduled results announcements.
- No upcoming MS medicine decision date could be confirmed in the FDA sources reviewed. FDA drug review process ↗
- No upcoming MS medicine opinion date could be confirmed in the EMA sources reviewed. Cenrifki’s recorded opinion and authorisation are past events, not upcoming decisions. EMA: Cenrifki regulatory record ↗
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error